is it possible that these companies having discussions with RVX are not interested in the same indications. So a Pharma that might be into CKD is wanting to aquire that point when it is clear several other end points are also being incorporated into the one trial"

Thought has crossed here too.  Better if BP acquires all rights, later, spin out applications to different pharmas.  Just a thought, the structure of RVX is complicated, too many fingers in the pie, Zeneith is the big one.  If PB wanted a clean right, they need to take out Zeneith.  They need to review rights sold of other countries too.  Lets hope a heard of legals are desending on RVX.  2020 is looking better.